Invacare Corporation (IVC)
(Delayed Data from NYSE)
$7.57 USD
+0.33 (4.56%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.57 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.57 USD
+0.33 (4.56%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.57 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Invacare (IVC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of -45.95% and 13.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Invacare (IVC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of -20.45% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 12.79% and 2.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Invacare (IVC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of -60.47% and 2.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) Q3 Earnings Miss Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of -5.84% and 4.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 81.25% and 5.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 7.44% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Invacare (IVC) Q4 Earnings Top Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of 300% and 6.20%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Invacare (IVC) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invacare (IVC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of 40.00% and 0.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Invacare (IVC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Invacare (IVC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Invacare (IVC) stock based on the movements in the options market lately.
New Strong Sell Stocks for August 27th
by Zacks Equity Research
CDLX, UUUU, IVC, PSTX, and CYTK have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2021
Invacare (IVC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of -33.33% and 4.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Invacare (IVC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Divests Minority Share of Q2 Solutions
by Zacks Equity Research
Quest Diagnostics' (DGX) divestment of Q2 solutions to IQVIA will allow IQVIA to lead Q2 Solutions on the next stage of its journey in central lab services as a global leader.
3 Beaten-Down MedTech Stocks to Scoop Up Amid the Pandemic
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks - IVC, MCK, HRC - which are expected to provide long-term gains in 2021.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to strong demand for COVID-19 testing and well-positioned growth strategy.
Henry Schein's (HSIC) New Deal Boosts Ambulatory Surgery Market
by Zacks Equity Research
Henry Schein's (HSIC) recent majority ownership in Stradis Healthcare will advance the former's commitment to offer specialty solutions to customers.
Integra's (IART) Neurosurgery Rebounds Despite Supply Issues
by Zacks Equity Research
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,
Illumina's (ILMN) Grail Merger in Trouble as FTC Files Suit
by Zacks Equity Research
According to FTC, the Illumina (ILMN) and Grail merger will diminish the scope of innovation in the U.S. market for MCED tests.
Here's Why You Should Retain Cooper Companies (COO) Now
by Zacks Equity Research
Investors remain optimistic about Cooper Companies (COO) backed by strong CSI and CVI product portfolios and its continued leadership in the specialty lenses market.
DENTSPLY SIRONA (XRAY) at a 52-Week High: What's Driving It?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) is optimistic about growth in CAD/CAM business arm along with its recent product launch and strategic buyouts.
Here's Why You Should Buy Align Technology (ALGN) Now
by Zacks Equity Research
Investors continue to be optimistic about Align Technology (ALGN) on robust international performance and continued portfolio expansion.